QAM
CRSP icon

QCI Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

QCI Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$226K Buy
2,015
+500
+33% +$62.8K 0.01% 142
2021
Q2 		$245K Buy
+1,515
New +$184K 0.01% 135

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

QCI Asset Management's CRSP Position: Q3 2021 in Review

QCI Asset Management increased its CRISPR Therapeutics (CRSP) stake by 33% in Q3 2021, buying an estimated $62.8K and bringing the position to 2,015 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #142.

QCI Asset Management first reported a position in CRSP in Q2 2021 and has held it in 2 quarters since. The position peaked at $245K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • QCI Asset Management held 2,015 shares of CRISPR Therapeutics worth $226K as of Q3 2021.
  • QCI Asset Management bought 500 CRISPR Therapeutics shares in Q3 2021, an estimated $62.8K.
  • CRISPR Therapeutics made up 0.01% of QCI Asset Management's portfolio in Q3 2021, its #142 holding.
  • QCI Asset Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • QCI Asset Management's CRISPR Therapeutics position peaked at $245K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on QCI Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.